news
Alterity’s ATH434 improves Parkinson’s-related gastrointestinal dysfunction
ATH434 reversed some of the gastrointestinal damage to the enteric nervous system associated with Parkinson's disease in a pre-clinical study.
List view / Grid view
Pharmacology
news
PANACEA consortium to increase global access to NMR spectroscopy
The Pan-European Solid-State NMR Infrastructure for Chemistry-Enabling Access will offer researchers access to over 30 NMR spectrometers.
news
Psilocybin spurs growth of neural connections lost in depression in vivo
Research from Yale University has shown that psilocybin, given to mice, triggered an increase in connections between neurons.
news
Antidepressants inhibit growth of pancreatic and colon cancers in mice
Scientists have discovered that approved antidepressant drugs cause immune cells to recognise and eliminate tumour cells in mouse models.
news
NINDS awards Sinopia $3.3m for development of Parkinson’s drug candidate
Sinopia has been awarded a $3.3 million Fast-Track SBIR grant to fund the study for its small molecule candidate for Parkinson’s disease.
news
Promising pre-clinical data announced for Parkinson’s drug
Stealth BioTherapeutics reported positive data from a pre-clinical study evaluating SBT-272 in a murine model of Parkinson's disease.
news
Sanofi acquires Translate Bio for mRNA therapeutic development
Sanofi has completed the acquisition of mRNA therapeutics company Translate Bio for a total of approximately $3.2 billion.
news
MEPs demand action plan to end animal testing in Europe
MEPs have requested that the EU adopts new plans to phase out the use of animals in scientific research and testing, focusing on alternatives instead.
article
Delivering gene therapies to the brain to treat Alzheimer’s
Dr Ronald G Crystal, Professor and Chairman of the Department of Genetic Medicine, Weill Cornell Medical College, spoke to Drug Target Review’s Victoria Rees about his research into Alzheimer’s disease and why gene therapies represent a promising area of research for neurodegenerative conditions.
news
Intranasal COVID-19 vaccine shown to be effective in animal models
A nasal spray of the COVID-19 Vaccine Oxford/AstraZeneca was found to protect hamsters and monkeys against SARS-CoV-2 in an NIH study.
news
CureVac and GSK COVID-19 vaccine shows promise in pre-clinical study
CureVac and GSK's second-generation mRNA COVID-19 vaccine candidate, CV2CoV, demonstrated improved immune response in a pre-clinical study.
article
Exclusive report: AI & Informatics: Drug discovery and development
In this original report, find an in-depth analysis of AI and informatics within imaging, synthetic biology, drug screening and drug design. Featured interviews with experts from AstraZeneca, Auransa, PolarisQB and Chalmers University of Technology.
news
Triple drug combination shows promise for pancreatic cancer treatment
MIT researchers have shown that a combination of three drugs can eliminate pancreatic tumours in mice, possibly leading to new therapies.
news
Licensed drug may reduce COVID-19 infection by 70 percent
Fenofibrate and its active form, fenofibric acid, have been shown to significantly reduce COVID-19 infection in human cells.
news
Novel database could accelerate drug repurposing for various diseases
NICEdrug.ch is an open-access database that may help scientists assess potential drugs for a range of diseases more quickly.
